April 3, 2024 article by Sasha Chavkin, Caitlin Gilbert, Anjali Tsui and Anahad O’Connor in The Washington Post.

By sponsoring dietitians on social media and funding their own studies, General Mills and other cereal brands are shifting the narrative away from the detrimental physical effects of a high-carbohydrate diet, and highlighting the psychological issues effecting people with sugar addiction.

“General Mills has toured the country touting anti-diet research it claims proves the harms of ‘food shaming.’ It has showered giveaways on registered dietitians who promote its cereals online with the hashtag #DerailTheShame, and sponsored influencers who promote its sugary snacks. The company has also enlisted a team of lobbyists and pushed back against federal policies that would add health information to food labels…

“The company has spent more than $2 million in 2022 and 2023 lobbying the federal government, according to data from OpenSecrets, a nonprofit group.

“Efforts by the FDA to regulate food labels have sparked some of the fiercest opposition from General Mills and other leading cereal producers.

“Last February, General Mills and fellow cereal giants Kellogg and Post Consumer Brands threatened legal action over a proposed rule to limit what they are allowed to promote as healthy.”


Read More

Let's start with the truth!

Support the Broken Science Initiative.
Subscribe today →

Leave A Comment

recent posts

    If you're seeing this page, you are not currently logged into a profile with access to Affiliate Owners / Medical.

    At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.

    The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.

    An abbreviated version of this discussion is available here, for free.

    At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.

    Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.

    The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.

    An abbreviated version of this discussion is available here, for free.

    MetFix and BSI Members can view the full 54-minute video.